Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR408701 versus docetaxel in previously treated metastatic nonsquamous NSCLC with CEACAM5-positive tumors
2024-515101-26-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Progression free survival and Overall survival. Started Nov 2024; status: completed.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515101-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515101-26-00.